Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like FDA Slaps Lupin With Form 483 for Risk of Contamination, Lack of In-Process Testing August 30, 2022 In Wake of Gantenerumab’s Failure, Roche Scraps All Studies December 1, 2022 Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree August 16, 2018